

## Financial Disclosures

The Biomarker Meeting seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of BIOMARKER participants. In doing so, the BIOMARKER Meeting recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

### Educational Content Development

The BIOMARKER Meeting requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

### Presenters

The BIOMARKER Meeting considers financial relationships to create actual conflicts of interest when Presenters or their immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Presenter) have both a financial relationship with a commercial interest and the opportunity to affect the policy of the BIOMARKER Meeting of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias.

All presenters of CME content should familiarize themselves with the policy of the BIOMARKER Meeting of CME based on the CME provider of the Meeting – [EACCME](#).

All BIOMARKER Faculty presenting CME are required to disclose to the activity audience the following information prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services within the past 12 months. The BIOMARKER Meeting defines "relevant" financial relationships as those with a commercial ophthalmic interest and the opportunity to affect the content of CME about the products or services of that commercial ophthalmic interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

NOTE: All presenters are required to report financial disclosures, using the codes below. An individual's financial disclosures for the 1<sup>st</sup> Biomarker Meeting are listed in this Section.

### Biomarker Financial Disclosure Codes

| Category             | Code | Description   |
|----------------------|------|---|
| None                 | N    | No financial relationships  |
| Consultant           | C    | Consultant fee, paid advisory boards<br>Advisor fees for attending a meeting (for the past 1 year)  |
| Employee             | E    | Employed by a commercial entity   |
| Lecture fees         | L    | Lecture fees (honoraria), travel fees or reimbursements when<br>Speaking at the invitation of a commercial entity<br>(for the past 1 year)  |
| Equity owner         | O    | Equity ownership/stock options or publicly or privately traded<br>firms (excluding mutual funds) with manufacturers of commercial ophthalmic<br>products or providers of commercial ophthalmic services |
| Patents /<br>Royalty | P    | Patents and/or royalties that might be viewed as creating a<br>potential conflict of interest   |
| Grant support        | S    | Grant support for the past 1 year (all sources) and all sources<br>Used for this project if this form is an update for a specific<br>talk or publication with no time limitation                        |

## Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

### John Aitken

No financial relationships N

### Signe Altmäe

No financial relationships N

### Francesca Ann Bahr

VitrolifeA/S E

### Kurt Barnhart

No financial relationships N

### Christopher Barratt

MRC S

EIC MHR L

### Natalia Basile

No financial relationships N

### Siladitya Bhattacharya

No financial relationships N

### Ernesto Bosch

Roche S

Angellini S

MSD L, C

Finox L

Tocopherx L

Ovascience L

HRT pharma L

Ferring C

### Gloria Calderon

No financial relationships N

### Ana Cobo

No financial relationships N

### Hilary Critchley

Bayer Pharma AG S, L

PreLem SA (PEARL IV) S, L

Study

AbbVie Incorporated L

Vifor Pharma UK Ltd L

### Eftychia Dimitriadou

No financial relationships N

### Diego Ezcurra

No financial relationships N

### David Gardner

Vitrolife AB, Sweden S

### Nicola Garrido

No financial relationships N

### Tamara Garrido Gómez

No financial relationships N

### Linda Giudice

National Institutes of Health S

Merck O

Pfizer O

### David Jimenez Moreno

No financial relationships N

### Kaarel Krjutškov

No financial relationships N

### Lalit Kumar

No financial relationships N

### Nick Macklon

Merck Serono S, L

Ferring L

MSD L

Anecova L

IBSA L

### Julio Martín

Igenomix E

### Marcos Meseguer

No financial relationships N

### Lodovico Parmegiani

No financial relationships N

### María Eugenia Póo

No financial relationships N

### Klaus Rink

No financial relationships N

### Eugenia Rocafort

No financial relationships N

### Carmen Rubio

No financial relationships N

### María Ruiz-Alonso

No financial relationships N

### Denny Sakkas

Ferring S

Fertilitech L

ORIGIO L

Good Start Genetics L

### Carlos Simón

EMD Serono S

OvaScience Inc L

Serono Symposia C

International Foundation

Equipo IVI O

Igenomix SL O

### Olga Tšuiiko

No financial relationships N

### Diana Valbuena

No financial relationships N

### Joris Vermeesch

Patents licensed to Agilent P

### Felipe Vilella Mitjana

No financial relationships N

### Masoud Zamani Esteki

No financial relationships N